Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence

We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer.Topics include:Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrenceBalancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatmentDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly